financetom
Business
financetom
/
Business
/
Darden Restaurants Insider Sold Shares Worth $2,390,707, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Darden Restaurants Insider Sold Shares Worth $2,390,707, According to a Recent SEC Filing
Jan 22, 2025 2:29 PM

05:11 PM EST, 01/22/2025 (MT Newswires) -- Matthew R Broad, Senior Vice President, General Counsel, on January 21, 2025, sold 12,759 shares in Darden Restaurants ( DRI ) for $2,390,707. Following the Form 4 filing with the SEC, Broad has control over a total of 14,328 shares of the company, with 14,328 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/940944/000122520825000739/xslF345X05/doc4.xml

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Real estate commission antitrust settlements face legal objections
Real estate commission antitrust settlements face legal objections
Apr 15, 2024
April 15 (Reuters) - One of the country's largest residential homebuilders has asked a U.S. judge not to approve $208 million in settlements resolving claims that major home brokerages conspired to keep real estate commissions artificially high. Atlanta-based homebuilder PulteGroup ( PHM ) in a filing on Friday questioned the adequacy of the proposed deals, which would resolve antitrust claims...
Edgewise Therapeutics Reports 'Positive' Two-Year Results From Becker Muscular Dystrophy Trial
Edgewise Therapeutics Reports 'Positive' Two-Year Results From Becker Muscular Dystrophy Trial
Apr 15, 2024
04:58 PM EDT, 04/15/2024 (MT Newswires) -- Edgewise Therapeutics ( EWTX ) said late Monday that an open-label trial of sevasemten in adults with Becker muscular dystrophy showed positive two-year topline results. Sevasemten was well-tolerated in 12 participants with no adverse event-related discontinuation or dose reductions, the firm said. The results from the trial further support the hypothesis that a...
Progress Software Insider Sold Shares Worth $1,020,000, According to a Recent SEC Filing
Progress Software Insider Sold Shares Worth $1,020,000, According to a Recent SEC Filing
Apr 15, 2024
04:56 PM EDT, 04/15/2024 (MT Newswires) -- David Krall, Director, on April 11, 2024, sold 20,000 shares in Progress Software ( PRGS ) for $1,020,000. Following the Form 4 filing with the SEC, Krall has control over a total of 86,641 shares of the company, with 86,641 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/876167/000087616724000082/xslF345X03/wk-form4_1713214338.xml ...
ORIC Pharmaceuticals Doses First Patients in Expansion Groups in Phase 1b Trial of ORIC-114 to Treat Lung Cancer
ORIC Pharmaceuticals Doses First Patients in Expansion Groups in Phase 1b Trial of ORIC-114 to Treat Lung Cancer
Apr 15, 2024
05:00 PM EDT, 04/15/2024 (MT Newswires) -- ORIC Pharmaceuticals ( ORIC ) said late Monday it dosed the first patients in three dose expansion groups in a phase 1b trial of ORIC-114 in people with lung cancer. The phase 1b expansion part of the study will assess the safety and efficacy of the candidate drug at the provisional recommended phase...
Copyright 2023-2026 - www.financetom.com All Rights Reserved